WEEKLY WRAP-UP

13TH JULY - 17TH JULY 2026

HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

DOMESTIC:

- Amara Raja to phase Li-ion cell rollout with focus on standard battery cells
- Warburg Pincus buys Integrace Pvt. Ltd for Rs1200cr
- L&T embraces MS Copilot to boost workforce productivity
- Tata Capital raises USD400mn via 3.5-year overseas bond
- SBI Funds Management IPO subscribed 2.77x; retail sees strong response
- Wipro sees bigger AI role for IT firms
- NBCC bags Rs501.45cr contracts, biggest in Rajasthan, to build labs in 922 govt schools
- Vedanta charts USD5bn oil & gas push, targets sharp capacity expansion across businesses
- TCS secures tech contract for New York's JFK Airport's Rs1.8lk-cr terminal project
- Mahindra's Chakan plant crosses 3 million vehicle production milestone
- HCLTech to acquire Guardian India for USD10.5mn; 2k employees to transition
- SBI Mutual Fund CEO outlines 4 priorities to drive growth
- JSW MG Motor India to invest Rs1,400cr in Halol plant, launch four new vehicles this fiscal
- ACME Solar secures Rs2,647cr REC funding for peak power project
- Biocon receives EMA approval for insulin fill finish unit
- Powerica secures 100MW SECI wind project at Rs3.85/unit tariff
- Seamec secures USD5.21mn charter for offshore barge SEAMEC GLORIOUS
- Jubilant FoodWorks gets GST demand notice for Rs46.9cr, to challenge demand
- Welspun Corp wins Rs14bn orders
- Route Mobile signs a BTA
- Sigma Advanced Systems acquires UK based Bromford Precision Solutions
- Diamond Power Infrastructure secures contract worth Rs185cr from Adani Energy Solutions
- Heritage Foods Board approves acquisition of additional 20% stake in subsidiary
- RPG Life Sciences ties-up with Archerchem Healthcare to launch anti-inflammatory solution in India
- Aditya Birla Group acquires Shell's India renewables energy arm, Sprng Energy, for USD1.8bn
- ITC sees demand momentum sustaining in H2; bets on premiumisation and healthy products
- PC Jeweller Board approves QIP issue up to Rs1,000cr
- ITI secures order of Rs856.39cr from BSNL

ECONOMY:

- Crisil sees volatile FY27: Inflation to rise to 5.1%, growth to slow; RBI may hike rates
- Centre's net direct tax revenue rises 16.4% to Rs6.51trn so far this year
- RBI's deposit mobilisation drive attracts USD10-11bn

INDUSTRY:

- India's EV market could grow 5x by FY31
- Govt. invites bids to set up 10GWh grid scale ACC manufacturing
- Data centres and manufacturing may drive Rs50trn power investment, but risks hitting a transmission wall

HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

INITIATING TECHNICAL PICK:

Filatex India Ltd:

Reco Price-Rs61 | Target Price-Rs81 & 100 | Industry-Other Textile Products

COVERAGE NEWS:

Mankind Pharma Ltd: (i) The Board has approved the divestment of 100% stake in Broadway Hospitality Services Pvt. Ltd to AKRK Projects LLP for a cash consideration of Rs490mn, (ii) The Board has approved the incorporation of a WoS in Netherlands for a proposed investment of upto EUR5mn in one or more tranches.

Standard Engineering Technology Ltd: The Board has approved issue of equity shares on preferential basis for (i) 2,439,750 equity shares for an issue price of Rs293 per share and (ii) 2,218,431 equity shares for an issue price of Rs293 per share.

EMS Ltd: (i) The company has received an L1 status for an order value of approx. Rs1058.16mn from UP Jal Nigam (Urban). The order is expected to be executed in 24 months, (ii) The company has received an LoA from UP Jal Nigam, Varanasi for an estimated order value of Rs1028.47mn for laying of sewer network and house connection work. The order is expected to be executed in 24 months.

Alembic Pharmaceuticals Ltd: The company has received a warning letter (on 12th Jul'26) from the USFDA for its bioequivalence facility at Vadodara. The WL pertains to observation regarding the Informed Consent Form (ICF) in relation to a bioequivalence study. The observations do not relate to data integrity.

Timken India Ltd: The company has been awarded 4 Bureau of Indian Standards (BIS) licenses for its bearings product categories at its Bharuch and Jamshedpur plant.

Sun Pharmaceutical Industries Ltd: The company has received an approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa.

HBL Engineering Ltd: The company has received an order worth Rs240mn from Integral Coach Factory (ICF), Chennai for supply, installation, testing and commissioning of on-board Kavach loco equipment (Ver 4.0).

Alkem Laboratories Ltd: The company has acquired 79,36,50,794 equity shares at issue price of Rs13.86 per equity share aggregating to Rs11bn offered by Alkem Medtech Pvt. Ltd (WoS). The object for this was related to acquire atleast 51% and upto 55% of the total issued equity share capital of M/s Occlutech Holding AG.

The Week That Went By:

For most of the time, the Index oscillated within a very narrow range of 24,000-24,200. However, on the last day of the week, IT and several other heavyweights took the lead and pushed the Index higher to break through the range, ending the week at 24,334.30, up by 127.40 points. Among the sectors, IT was the best-performer, followed by Media, while the Capital Market Index declined by 2.81% and was the main laggard, with Realty also lagging. A divergence was observed in the markets as Nifty50 closed in green, while Mid and Smallcaps corrected by 0.97% and 0.62%, respectively, and lagged.

Nifty50=24,334.30 **Sensex30=78,151.45** **Nifty Midcap 100=62,428.05** **Nifty Smallcap100=19,296.30**

HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

NIFTY (WEEKLY)

BANK NIFTY (WEEKLY)

MARKET OUTLOOK

Nifty 50 has broken out of its consolidation range of 24,000–24,200 on the daily chart. However, a convincing move above the level of 24,500 will result in a major Cup and Handle Pattern Breakout. Until then, 24,500 is expected to act as the immediate resistance, while the support has shifted higher to 24,200. **BankNifty** is also approaching the end of its consolidation phase, with immediate resistance placed at 59,220 and support at 58,130. From a sectoral perspective, one should bring the **Auto segment** to the radar as it is nearing a Symmetrical Triangle breakout, indicating the potential resumption of its primary uptrend. The **Capital Markets** Index continues to trade within a Symmetrical Triangle formation, and a decisive breakout on either sides is likely to determine the next directional move. The **IT space** has rebounded from a crucial support zone, accompanied by a double bullish RSI divergence, suggesting improving momentum and the possibility of a trend reversal. Meanwhile, the **Pharma sector** has experienced a phase of profit booking following a bearish RSI divergence. Nevertheless, the broader uptrend remains intact, and any further decline could provide better opportunities. After outperforming over the past two weeks, the **Realty segment** witnessed a healthy pullback. It concluded the week with a breakout from a Bullish Flag and Pole pattern, signalling the continuation of its uptrend. The earnings season has gathered pace, with several Nifty heavyweight constituents scheduled to announce their quarterly results over the weekend. Therefore, earnings-driven volatility is expected to influence Monday's trading session. Meanwhile, any escalation in geopolitical tensions in the Middle East could affect the Indian equities adversely.

HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	(0.09%)	HDFC Life	(0.62%)	Reliance	1.44%
Adani Ports	0.36%	Hindalco	(2.42%)	SBI Life	(1.86%)
Apollo Hospital	(0.34%)	HUL	(0.37%)	SBIN	0.66%
Asian Paints	0.50%	ICICI Bank	3.77%	ShriRam Finance	(1.50%)
Axis Bank	0.48%	Indigo	(1.00%)	Sun Pharma	0.06%
Bajaj Auto	2.80%	INFY	2.39%	Tata Consumer	(2.04%)
Bajaj Finserv	(3.33%)	ITC	(0.46%)	Tata Steel	(2.80%)
Bajaj Finance	3.16%	JioFin	0.09%	TCS	9.57%
BEL	(1.39%)	JSW Steel	(0.96%)	Tech Mahindra	7.91%
Bharti Airtel	(0.57%)	Kotak Bank	3.32%	TITAN	1.35%
Cipla	(1.56%)	LT	(3.30%)	TMPV	(0.62%)
Coal India	(0.64%)	M&M	1.59%	Trent	(2.10%)
Dr. Reddy's Labs	(2.90%)	Maruti	(0.33%)	UltraTech	(0.29%)
Eicher Motors	2.52%	Max Healthcare	(1.62%)	Wipro	0.22%
Eternal	(1.09%)	Nestle India	(1.53%)		
Grasim	(3.25%)	NTPC	(0.91%)		
HCL Tech	3.04%	ONGC	0.95%		
HDFC Bank	(0.45%)	PowerGrid	(0.14%)		

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

SECTORAL GAINER

The **IT space** soared by 4.34% and outshone the Benchmark Index. All the components ended the week in green territory, with **TCS (+9.57%)** and **Tech Mahindra (+7.91%)** being the top performers, followed by **Mphasis (+3.15%)** and **HCL Tech (+3.04%).** As shown in the above chart, the sector bounced from its extremely strong support zone with a **double bullish divergence in RSI,** which indicates a trend reversal.

SECTORAL LOSER

With a loss of 2.81%, the **Capital Market segment** lagged Nifty50. Among the constituents, a mixed performance was seen where **Groww (+2.55%)** and **IEX (+2.41%)** outperformed, while **UTI AMC** and **BSE** were the major laggards by declining **6.74%** & **6.11%**, respectively. The sector is oscillating within the **Symmetrical Triangle Pattern**, and a breakout on either sides will provide a directional move.

HIGHLIGHTS OF THE WEEK 13 July 2026-17 July 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai-400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com